A New Era in the Management of Hypertrophic Cardiomyopathy
Reviews in Cardiovascular Medicine · 30.10.2025 · 26 (10)
DOI: 10.31083/rcm44503 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 30.10.2025. Verfasst von Ana Perez-Asensio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital Universitario Puerta del Mar, 11007 Cadiz, Spain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation's Big Beat Challenge award to CureHeart.
Abstract (Originalsprache)
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease. Depending on the predominant phenotype, management can be tailored to address left ventricular outflow tract obstruction, heart failure, arrhythmia control, and/or sudden cardiac death prevention. This review highlights recent advances that have transformed the therapeutic landscape of HCM. Modern imaging techniques have improved sudden cardiac death risk stratification. The development of myosin inhibitors represents a paradigm shift in the treatment of symptomatic obstructive HCM. Invasive septal reduction techniques have also evolved, with novel approaches such as percutaneous intramyocardial septal radiofrequency ablation and transapical beating-heart septal myectomy. Finally, gene-targeted therapies including replacement, editing and silencing approaches, are emerging as promising strategies for HCM management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, Hospital Universitario Puerta del Mar, 11007 Cadiz, Spain.
- Cardiology Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
- Cardiology Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.
- Radcliffe Department of Medicine, Division of Cardiovascular Medicine, University of Oxford, OX1 2JD Oxford, UK.
ORCID-Profile: Ana Perez-Asensio, Helena Llamas-Gomez, Cesar Jimenez-Mendez, Julian Palomino-Doza
Förderung
- British Heart Foundation's Big Beat Challenge award to CureHeart
Zitieren
APA
Perez-Asensio, A., Llamas-Gomez, H., Lara-Palomo, A., Villar-Ruiz, A., Jimenez-Mendez, C., & Palomino-Doza, J. (2025). A New Era in the Management of Hypertrophic Cardiomyopathy. Reviews in Cardiovascular Medicine, 26(10). https://doi.org/10.31083/rcm44503
Vancouver
Perez-Asensio A, Llamas-Gomez H, Lara-Palomo A, Villar-Ruiz A, Jimenez-Mendez C, Palomino-Doza J. A New Era in the Management of Hypertrophic Cardiomyopathy. Reviews in Cardiovascular Medicine. 2025;26(10). doi:10.31083/rcm44503
BibTeX
@article{PerezAsensio2025,
author = {Perez-Asensio, Ana and Llamas-Gomez, Helena and Lara-Palomo, Ana and Villar-Ruiz, Alberto and Jimenez-Mendez, Cesar and Palomino-Doza, Julian},
title = {A New Era in the Management of Hypertrophic Cardiomyopathy},
journal = {Reviews in Cardiovascular Medicine},
year = {2025},
volume = {26},
number = {10},
doi = {10.31083/rcm44503}
}
EUVIMED